# Xcellon Biologics: Transforming scientific advancements into life\-saving therapies\.

> Xcellon Biologics is an Antibody\-Drug Conjugate \(ADC\) CDMO in Rockville, MD, providing end\-to\-end bioconjugation, process development, and GMP manufacturing services\.

Generated by Yoast SEO v28.2, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Bioconjugation Configuration](https://xcellon.bio/bioconjugation-configuration/)
- [CRO Services](https://xcellon.bio/cro-services/)
- [Biosecurity](https://xcellon.bio/biosecurity/)
- [GMP Manufacturing](https://xcellon.bio/gmp-manufacturing/)
- [Advanced Data Analytics \& Machine Learning](https://xcellon.bio/advanced-data-analytics-machine-learning/)

## News
- [Xcellon Biologics Launches XSpec™, a New Bioconjugation Configurator](https://xcellon.bio/news/xcellon-bioconjugation-configurator-xspec/): Xcellon Biologics has launched XSpec™, a bioconjugation configurator that streamlines early\-stage program design for ADCs and other targeted therapeutics\.
- [ADC Manufacturing Capacity Is What Pharma Is Really Buying](https://xcellon.bio/news/xcellon-adc-manufacturing-capacity/): BioBuzz features Xcellon Biologics and COO Yuk Chiu in a look at why ADC manufacturing capacity is 2026's real industry bottleneck\.
- [Linden Lake Labs Portfolio Company CrossBridge Bio to Be Acquired by Eli Lilly and Company](https://xcellon.bio/news/crossbridge-bio-acquisition-lilly/): CrossBridge Bio to be acquired by Eli Lilly and Company for up to $300 million, marking an early platform milestone for Linden Lake Labs\.
- [Xcellon Biologics Launches Xcellerate Program to Support Early\-Stage Biotech Innovation](https://xcellon.bio/news/xcellerate-biotech-program/): Xcellon Biologics launches Xcellerate, a program designed to help early\-stage biotech companies accelerate ADC development and navigate the toughest phase between proof\-of\-concept and funding\.
- [Antibody Drug Conjugate CDMO Xcellon partners with Invenra](https://xcellon.bio/news/antibody-drug-conjugate-cdmo-xcellon-partners-with-invenra/): Invenra’s multispecific antibody platforms, together with Xcellon’s bioconjugation and manufacturing expertise, are advancing the development of complex biologics\.

## Events
- [Xcellon is sponsoring World ADC 2026](https://xcellon.bio/events/xcellon-world-adc-2026-glycan-conjugation/): Xcellon Biologics is proud to sponsor the World ADC 2025\. Come visit our booth and see our latest development in conjugation technologies and gene to IND service offerings\!

## Resources
- [Defining the Ideal ADC Linker: Design Principles and Performance Traits](https://xcellon.bio/resources_upload/ideal-adc-linker-design-whitepaper/)
- [Solving  for ADC  Manufacturing Complexity](https://xcellon.bio/resources_upload/adc-manufacturing-challenge-xcellon/)
- [Case Studies and Insights of Various Conjugation Methods](https://xcellon.bio/resources_upload/adc-conjugation-case-study-xcellon/)
- [Site\-Specific Glycan Conjugation Enables Robust Antibody–Drug Conjugates](https://xcellon.bio/resources_upload/site-specific-glycan-conjugation-robust-adcs/)

## Categories
- [Press Release](https://xcellon.bio/category/press-release/)
- [Blog](https://xcellon.bio/category/blog/)
- [News](https://xcellon.bio/category/news/)

## Optional
- [Sitemap index](https://xcellon.bio/sitemap_index.xml)